Development of influenza A(H7N9) candidate vaccine viruses with improved hemagglutinin antigen yield in eggs

Influenza and other Respiratory Viruses

Volumn 9, Issue 5, 2015, Pages 263-270

  Ridenour, Callie ^a   Johnson, Adam ^a   Winne, Emily ^b,c   Hossain, Jaber ^a   Mateu Petit, Guaniri ^a   Balish, Amanda ^a   Santana, Wanda ^b   Kim, Taejoong ^a   Davis, Charles ^a   Cox, Nancy J ^a   Barr, John R ^b   Donis, Ruben O ^a   Villanueva, Julie ^a   Williams, Tracie L ^b   Chen, Li Mei ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b NATIONAL CENTER FOR ENVIRONMENTAL HEALTH   (United States)

^c BATTELLE MEMORIAL INSTITUTE   (United States)

Author keywords

Antigen yield; H7N9; Hemagglutinin; Influenza; Serial passage; Vaccine

Indexed keywords

INFLUENZA VACCINE; VIRUS HEMAGGLUTININ; VIRUS PROTEIN; INFLUENZA VIRUS HEMAGGLUTININ;

AMINO ACID SUBSTITUTION; ANTIGENICITY; ARTICLE; CONTROLLED STUDY; GENETIC REASSORTMENT; HEMAGGLUTINATION INHIBITION; INFLUENZA VIRUS A H7N9; ISOTOPE DILUTION MASS SPECTROMETRY; MASS SPECTROMETRY; NONHUMAN; PRIORITY JOURNAL; REVERSE GENETICS; SEQUENCE ANALYSIS; ZYGOTE; ANIMAL; CHICK EMBRYO; EGG; FERRET; GENETICS; HUMAN; IMMUNOLOGY; INFLUENZA A VIRUS (H7N9); INFLUENZA, HUMAN; VIROLOGY; VIRUS CULTURE;

ANIMALS; CHICK EMBRYO; EGGS; FERRETS; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HUMANS; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; REVERSE GENETICS; SERIAL PASSAGE; VIRUS CULTIVATION;

EID: 84938878251     PISSN: 17502640     EISSN: 17502659     Source Type: Journal    
DOI: 10.1111/irv.12322     Document Type: Article

References (35)

1. Liu D, Shi W, Shi Y et al. Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses. Lancet 2013; 381:1926-1932.
2. Kilbourne ED, Schulman JL, Schild GC, Schloer G, Swanson J, Bucher D. Related studies of a recombinant influenza-virus vaccine. I. Derivation and characterization of virus and vaccine. J Infect Dis 1971; 124:449-462.
3. Harvey R, Wheeler JX, Wallis CL, Robertson JS, Engelhardt OG. Quantitation of haemagglutinin in H5N1 influenza viruses reveals low haemagglutinin content of vaccine virus NIBRG-14 (H5N1). Vaccine 2008; 26:6550-6554.
4. Abt M, de Jonge J, Laue M, Wolff T. Improvement of H5N1 influenza vaccine viruses: influence of internal gene segments of avian and human origin on production and hemagglutinin content. Vaccine 2011; 29:5153-5162.
5. Jing X, Phy K, Li X, Ye Z. Increased hemagglutinin content in a reassortant 2009 pandemic H1N1 influenza virus with chimeric neuraminidase containing donor A/Puerto Rico/8/34 virus transmembrane and stalk domains. Vaccine 2012; 30:4144-4152.
6. Robertson JS, Nicolson C, Harvey R et al. The development of vaccine viruses against pandemic A(H1N1) influenza. Vaccine 2011; 29:1836-1843.
7. WHO. WHO guidance on development of influenza vaccine reference viruses by reverse genetics. 2005; Available at: www.who.int/csr/resources/publications/influenza/WHO_CDS_CSR_GIP_2005_6.pdf. (Accessed 22 February 2015).
8. Hoffmann E, Krauss S, Perez D, Webby R, Webster RG. Eight-plasmid system for rapid generation of influenza virus vaccines. Vaccine 2002; 20:3165-3170.
9. Dong J, Matsuoka Y, Maines TR et al. Development of a new candidate H5N1 avian influenza virus for pre-pandemic vaccine production. Influenza Other Respir Viruses 2009; 3:287-295.
10. CBER/FDA. US Department of Health and Human Services, Guidance for Industry on Characterization and Qualification of Cell Substrates and Other Biological Materials Used in the Production of Viral Vaccines for Infectious Disease Indications. Washington, DC: Food and Drug Administration, Center for Biologics Evaluation and Research, 2010; Available at http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/default.htm (Accessed 20 February 2015).
11. Williams TL, Luna L, Guo Z et al. Quantification of influenza virus hemagglutinins in complex mixtures using isotope dilution tandem mass spectrometry. Vaccine 2008; 26:2510-2520.
12. Santana WI, Williams TL, Winne EK, Pirkle JL, Barr JR. Quantification of viral proteins of the avian H7 subtype of influenza virus-an isotope dilution mass spectrometry method applicable for producing more rapid vaccines in the case of an influenza pandemic. Anal Chem 2014; 86:4088-4095.
13. Klimov A, Balish A, Veguilla V et al. Influenza virus titration, antigenic characterization, and serological methods for antibody detection. Methods Mol Biol 2012; 865:25-51.
14. Stohr K, Bucher D, Colgate T, Wood J. Influenza virus surveillance, vaccine strain selection, and manufacture. Methods Mol Biol 2012; 865:147-162.
15. Fulvini AA, Ramanunninair M, Le J et al. Gene constellation of influenza A virus reassortants with high growth phenotype prepared as seed candidates for vaccine production. PLoS ONE 2011; 6:e20823.
16. O'Neill E, Donis RO. Generation and characterization of candidate vaccine viruses for prepandemic influenza vaccines. Curr Top Microbiol Immunol 2009; 333:83-108.
17. Gubareva LV, Wood JM, Meyer WJ et al. Codominant mixtures of viruses in reference strains of influenza virus due to host cell variation. Virology 1994; 199:89-97.
18. Gambaryan AS, Matrosovich TY, Philipp J et al. Receptor-binding profiles of H7 subtype influenza viruses in different host species. J Virol 2012; 86:4370-4379.
19. Suzuki Y, Kato H, Naeve CW, Webster RG. Single-amino-acid substitution in an antigenic site of influenza virus hemagglutinin can alter the specificity of binding to cell membrane-associated gangliosides. J Virol 1989; 63:4298-4302.
20. EMA. Guideline on Influenza Vaccines - Quality Module. Committee for Human Medicinal Products (CHMP) [serial on the Internet]. 2013: Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2013/03/WC500139747.pdf. (Accessed 22 February 2015)
21. WHO. Antigenic and genetic characteristics of zoonotic influenza viruses and development of candidate vaccine viruses for pandemic preparedness. 2013; Available at http://www.who.int/influenza/vaccines/virus/201302_h5h7h9_vaccinevirusupdate.pdf. (Accessed 22 February 2015)
22. Jadhao SJ, Achenbach J, Swayne DE, Donis R, Cox N, Matsuoka Y. Development of Eurasian H7N7/PR8 high growth reassortant virus for clinical evaluation as an inactivated pandemic influenza vaccine. Vaccine 2008; 26:1742-1750.
23. Ulmer JB, Valley U, Rappuoli R. Vaccine manufacturing: challenges and solutions. Nat Biotechnol 2006; 24:1377-1383.
24. Brown LE, Murray JM, White DO, Jackson DC. An analysis of the properties of monoclonal antibodies directed to epitopes on influenza virus hemagglutinin. Arch Virol 1990; 114:1-26.
25. Takahashi T, Hashimoto A, Maruyama M et al. Identification of amino acid residues of influenza A virus H3 HA contributing to the recognition of molecular species of sialic acid. FEBS Lett 2009; 583:3171-3174.
26. Gambaryan AS, Matrosovich MN, Bender CA, Kilbourne ED. Differences in the biological phenotype of low-yielding (L) and high-yielding (H) variants of swine influenza virus A/NJ/11/76 are associated with their different receptor-binding activity. Virology 1998; 247:223-231.
27. Guarnaccia T, Carolan LA, Maurer-Stroh S et al. Antigenic Drift of the Pandemic 2009 A(H1N1) Influenza Virus in a Ferret Model. PLoS Pathog 2013; 9:e1003354.
28. Xu R, de Vries RP, Zhu X et al. Preferential recognition of avian-like receptors in human influenza A H7N9 viruses. Science 2013; 342:1230-1235.
29. Yang H, Carney PJ, Chang JC, Villanueva JM, Stevens J. Structural analysis of the hemagglutinin from the recent 2013 H7N9 influenza virus. J Virol 2013; 87:12433-12446.
30. Hensley SE, Das SR, Bailey AL et al. Hemagglutinin receptor binding avidity drives influenza A virus antigenic drift. Science 2009; 326:734-736.
31. Chen Z, Baz M, Lu J et al. Development of a high yield live attenuated H7N9 influenza vaccine that provides protection against homologous and heterologous H7 wild-type viruses in ferrets. J Virol 2014; 88:7016-7023.
32. Ramanunninair M, Le J, Onodera S et al. Molecular signature of high yield (growth) influenza a virus reassortants prepared as candidate vaccine seeds. PLoS ONE 2013; 8:e65955.
33. Mitnaul LJ, Matrosovich MN, Castrucci MR et al. Balanced hemagglutinin and neuraminidase activities are critical for efficient replication of influenza A virus. J Virol 2000; 74:6015-6020.
34. Myers JL, Wetzel KS, Linderman SL, Li Y, Sullivan CB, Hensley SE. Compensatory hemagglutinin mutations alter antigenic properties of influenza viruses. J Virol 2013; 87:11168-11172.
35. Wagner R, Wolff T, Herwig A, Pleschka S, Klenk HD. Interdependence of hemagglutinin glycosylation and neuraminidase as regulators of influenza virus growth: a study by reverse genetics. J Virol 2000; 74:6316-6323.